Commentary
Deep venous thrombosis is a common medical disorder, with an annual incidence of 1 per 1,000 adults. 2 In addition to the initial symptomatology and need for anticoagulation, the development of a deep venous thrombosis is associated with increased risks of pulmonary embolism, recurrent deep venous thrombosis, and post-thrombotic syndrome.
2-4
Data have suggested that 28% to 50% of all deep venous thromboses lead to pulmonary embolism, and the 6-month recurrence rate for deep venous thromboses is approximately 7%. 2 Additionally, up to 50% of patients may develop postthrombotic syndrome, 3, 4 which is a constellation of symptoms resulting from chronic venous insufficiency caused by the initial deep venous thrombosis. Symptoms include pain, swelling, skin pigmentation changes, and venous ulcers. 3, 4 Patients with post-thrombotic syndrome also have significantly increased longterm health care costs, as well as decreased quality of life. 5, 6 This review demonstrated that, regardless of delivery method, using thrombolytic agents resulted in improved rates of clot lysis and venous patency, as well as decreased rates of post-thrombotic syndrome (number needed to treat¼4). However, use of thrombolytic agents was also associated with an increased risk of bleeding (number needed to harm¼17). Most of the studies demonstrating the increased bleeding risks were performed several decades before, when the exclusion criteria were less strict. For example, the 3 cases of intracranial hemorrhage occurred before 1990 in studies with fewer exclusion criteria [7] [8] [9] compared with the most recent study by Enden et al, 10 which mirrored the current exclusion criteria for thrombolysis in acute stroke.
It is important to consider a number of limitations when interpreting these data. Most of the studies were small, with 9 having fewer than 50 subjects. Additionally, there were significant variations in the type and dose of thrombolytic agent, technique used to deliver the agent, location of the deep venous thrombosis, and outcome measures with respect to postthrombotic syndrome scales and degrees of deep venous thrombosis clearance. Not all studies provided information about the use of supportive therapy for post-thrombotic syndrome (eg, leg elevation, compression stockings), authors included trials assessing any thrombolytic agent, any dosing regimen of lytic agents, and both systemic and catheter-directed thrombolysis. Primary outcomes included any improvement in venous patency, complete clot lysis, bleeding complications (separated into intracranial hemorrhage and all other bleeding complications), and post-thrombotic syndrome. Secondary outcomes included recurrent deep venous thrombosis, pulmonary embolism, assessments of venous function, quality of life, and cost comparisons. Two authors reviewed and identified appropriate trials for inclusion in the review.
DATA EXTRACTION AND SYNTHESIS
Two authors independently extracted data, using a standardized data extraction form designed by the Cochrane Vascular group. Study quality was independently assessed by groups of 2 review authors using the Cochrane and Cochrane Vascular guidelines, as well as the Cochrane risk-of-bias tool.
1 Dichotomous outcomes were assessed with relative risk and 95% confidence intervals. The studies were evaluated for heterogeneity by visual inspection of forest plots and the c 2 test. If statistical heterogeneity was identified (P<.05), the authors used a random-effects model; otherwise, they evaluated the data with a fixed-effects model. The studies were pooled for meta-analysis if evaluation revealed a sufficiently similar outcome measure and assessment data.
which may have affected the degree of post-thrombotic syndrome symptoms. The inclusion and exclusion criteria also differed over time. Although this may have reduced the bleeding risk in later trials, it also decreased the proportion of eligible patients. Furthermore, only a few studies had extended follow-up (ie, longer than 1 year), and there were limited data assessing the risk of recurrent deep venous thrombosis or pulmonary embolism. Finally, the studies did not assess other adverse events, such as allergic or anaphylactic reactions.
Given these findings, providers can consider adjunctive thrombolytic agents, but should consider the risks and benefits, as well as the limitations of the current data. Future studies should provide more data on the risk of recurrent deep venous thrombosis, risk of pulmonary embolism, and long-term effects. Additionally, studies should identify which patients are most likely to benefit from thrombolytic agents (eg, age, location of deep venous thrombosis, timing of deep venous thrombosis occurrence), which is the preferred delivery method, and the effect of mechanical thrombectomy. 
